An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared with 5-FU and Cisplatin in Patients with Metastatic Diffuse Gastric Cancer Previously Untreated with Chemotherapy (TPU-S1303)

Trial Profile

An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared with 5-FU and Cisplatin in Patients with Metastatic Diffuse Gastric Cancer Previously Untreated with Chemotherapy (TPU-S1303)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Fluorouracil
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DIGEST
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 12 Sep 2017 Results of identification of patient population with longer survival by using clinical covariate model data from FLAGS and DIGEST phase III trials presented at the 42nd European Society for Medical Oncology Congress
    • 01 Sep 2017 According to results published in the Annals of Oncology, the trial terminated early due to slow patient accrual and the primary end point (overall survival) was not met.
    • 01 Sep 2017 Status changed from active, no longer recruiting to discontinued, according to results published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top